The Unintended Impact of Opioid Prescribing Guidelines: Part 1
Drug Topics
DECEMBER 5, 2023
The CDC first released opioid prescribing guidelines in 2016.
Tue.Dec 05, 2023
252 
STAT+: Pfizer plans to depart BIO
STAT
DECEMBER 5, 2023
WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the decision. The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
New Risk Factor Found for Future Cardiovascular Disease in Patients With Systemic Lupus Erythematosus
Pharmacy Times
DECEMBER 5, 2023
Investigators found that positive antiphospholipid antibodies and traditional risk factors were associated with atherosclerotic cardiovascular disease.
STAT+: CVS’s new drug payment plan won’t lower patients’ prices, experts warn
STAT
DECEMBER 5, 2023
CVS Health is promising to simplify how its pharmacies get paid for drugs. But that doesn’t mean the drugs will get cheaper. The country’s biggest pharmacy chain said it’s switching to a system where pharmacy benefit managers, employers, and other insurers pay for drugs based on the cost of the drug plus a set markup and dispensing fee.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Long-term Chia Seed Supplementation May Significantly Lower Systolic Blood Pressure
Pharmacy Times
DECEMBER 5, 2023
Chia seeds are a nutrient dense product that are rich in fiber and omega-3 fatty acids, and could have a hypocholesterolemic effect when ingested.
Is the flu shot market a slam dunk for mRNA vaccines? Experts aren’t so sure
STAT
DECEMBER 5, 2023
Here are two things that are true. The world needs more effective flu vaccines. And pharmaceutical companies that learned of the vaccine-making power of the messenger RNA platform during the Covid-19 pandemic need new markets for their technology.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
STAT+: J&J to emphasize cancer drugs and stop much of its vaccine research
STAT
DECEMBER 5, 2023
Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease. To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.
Study Finds Inavolisib Combination Treatment Improved PFS in Patients With Breast Cancer
Pharmacy Times
DECEMBER 5, 2023
In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.
STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO
STAT
DECEMBER 5, 2023
WASHINGTON — The Biotechnology Innovation Organization has chosen longtime biotech executive and rare disease advocate John Crowley as its new CEO, the organization announced Tuesday. Crowley came to biotech when his children were diagnosed with a rare genetic neuromuscular disease. He started working at Bristol-Myers Squibb, and started Novazyme, which was eventually successful in creating an enzyme replacement therapy for Pompe disease.
FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments
Pharmacy Times
DECEMBER 5, 2023
Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Adventist, Blue Shield of California contract talks fail
Fierce Healthcare
DECEMBER 5, 2023
Blue Shield of California members will no longer be covered across 17 Adventist Health hospitals, the hospital system recently announced. | Blue Shield of California and Adventist Health were unable to reach a new contract agreement, leaving members without coverage since Dec. 1. The hospital system says they remain open to future discussions.
As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth
Fierce Pharma
DECEMBER 5, 2023
As Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs.
Study: Older Patients With Actinic Keratoses at Increased Risk of Skin Cancer
Pharmacy Times
DECEMBER 5, 2023
Patients enrolled in the study had substantial absolute risks and elevated relative risks, suggesting that AKs may be a clinical marker of UV exposure and increased skin cancer risk.
Pharmacist-Led Intervention Could Help Lower Rates of Inappropriate Aspirin Use
Drug Topics
DECEMBER 5, 2023
Updated guidance from the United States Preventive Services Task Force advises against low-dose aspirin use as a primary prevention of atherosclerotic cardiovascular disease in certain populations who have bleeding risks.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Removing Barriers That Limit Young Men at Risk for HIV Will Improve Access to PrEP
Pharmacy Times
DECEMBER 5, 2023
The study authors note that increasing education, implementing online services, and removing stigma can help improve the uptake of PrEP in this population.
STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
STAT
DECEMBER 5, 2023
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to a startup his designs for a powerful new type of therapy, called CAR-T, that would re-engineer a child’s own immune cells to target cancer. The deal proved be a mixed blessing. The therapy eventually reached market as Breyanzi, one of three CAR-Ts approved for adult leukemia.
CVS Health revamps pharmacy reimbursement model amid scrutiny on high drug prices
Fierce Healthcare
DECEMBER 5, 2023
CVS Health is overhauling the way it reimburses its pharmacies for prescription medications as the healthcare industry faces increased scrutiny for high drug prices. | CVS Health is overhauling the way it reimburses its pharmacies for prescription medications as the healthcare industry faces increased scrutiny on high drug prices.
STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million
STAT
DECEMBER 5, 2023
Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year. ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Many employed docs say non-physician practice ownership cuts quality, survey finds
Fierce Healthcare
DECEMBER 5, 2023
Nearly 60% of doctors who practice as employees of hospitals and other corporate entities say that non-physician practice ownership results in lower quality patient care, per a new survey. | Most docs surveyed cited decreased time with patients and greater focus on financial success as elements negatively affecting quality at non-physician-owned medical practices, with 70% saying their employer uses incentives or penalties to have them see more patients a day.
Reinvigorating the Cancer Moonshot with empowered patients
pharmaphorum
DECEMBER 5, 2023
Reinvigorating the Cancer Moonshot with empowered patients Mike.
STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts
STAT
DECEMBER 5, 2023
NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines? Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030. Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.
Watch DSN: The future of health care and pharmacy at Walgreens
Drug Store News
DECEMBER 5, 2023
DSN spoke to Dr. Clive Fields, co-founder and chief medical officer at VillageMD, to discuss the challenges that lie ahead for the healthcare space.
FDA Grants Breakthrough Designation to Johnson & Johnson’s Novel Treatment for HR-NMIBC
PharmExec
DECEMBER 5, 2023
TAR-200 has a novel targeted releasing system for the treatment of patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer who are ineligible for bladder removal surgery.
Creating a future where the healthcare ecosystem works for everyone
pharmaphorum
DECEMBER 5, 2023
In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Ari Tulla, CEO and co-founder of Elo Health, about his ‘big vision’ to transform food – changing it from a leading cause of disease to the medicine it can be.
Phase III data for novel telomerase inhibitor released
European Pharmaceutical Review
DECEMBER 5, 2023
Results from Geron’s Phase III IMerge trial evaluating its first-in-class investigational telomerase inhibitor imetelstat, have shown long-term and durable response in participants with a rare haematologic malignancy. Efficacy of the treatment was compared to placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs).
Rural Patients Utilize ED for Migraine at Higher Rates
Drug Topics
DECEMBER 5, 2023
These populations are also more likely to receive opioid analgesic therapies.
Travere cuts workforce by 20% as Filspari's prospects are up in one rare kidney disease, down in another
Fierce Pharma
DECEMBER 5, 2023
Travere Therapeutics will reduce its workforce by 20%, with the jo | Travere Therapeutics will reduce its workforce by 20%, with the job cuts focused on “non-field-based employees,” the company said on Tuesday. The layoffs are part of a shake-up of the San Diego-based company as it focuses on its launch of kidney drug Filspari and develops pegtibatinase as a potential treatment for the metabolic disorder homocystinuria (HCU).
Q&A: Tackling the rise of fake anti-obesity drugs on the market
Pharmaceutical Technology
DECEMBER 5, 2023
Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.
BMS chases MSD/Seagen with first-line bladder cancer filing
pharmaphorum
DECEMBER 5, 2023
BMS chases MSD/Seagen with first-line bladder cancer filing Phil.
Roche to advance novel obesity and diabetes treatments
European Pharmaceutical Review
DECEMBER 5, 2023
Roche has agreed to acquire biotech Carmot Therapeutics for an upfront purchase price of $2.7 billion, enabling the Swiss pharma company to add a range of incretin treatments for obesity and diabetes to its portfolio. Incretins are “gut hormones that are secreted after food intake and play a role in modulating blood glucose by stimulating insulin secretion and suppressing appetite,” Roche highlighted.
Roche bounces back in PIK3 with inavolisib data
pharmaphorum
DECEMBER 5, 2023
Roche bounces back in PIK3 with inavolisib data Phil.
CVS launches new pharmacy reimbursement model, brand for health services segment
Drug Store News
DECEMBER 5, 2023
CVS is introducing CostVantage and Caremark TrueCost to drive aligned incentives and deliver a more transparent and sustainable reimbursement model.
STAT+: Senate panel considers Medicare policy fixes to drug shortages
STAT
DECEMBER 5, 2023
WASHINGTON — Members of the Senate Finance Committee took their first steps today toward using Medicare payment policy to fix drug shortages. Drug shortages are particularly vexing because they’re mostly caused by policies within the control of the government, as opposed to outside shocks such as natural disasters. Instead, it’s economic factors — the complicated way Medicare pays hospitals or the dominance of group purchasing organizations that buy hospital drugs &#x
Let's personalize your content